EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 213 / Numéro 3-4 (2019) Biologie Aujourd’hui, 213 3-4 (2019) 121-129 References
Free Access
Issue
Biologie Aujourd’hui
Volume 213, Number 3-4, 2019
Page(s) 121 - 129
DOI https://doi.org/10.1051/jbio/2019015
Published online 12 décembre 2019
  • Abad, S., Fole, A., Del Olmo, N., Pubill, D., Pallàs, M., Junyent, F., Camarasa, J., Camins, A., Escubedo, E. (2014). MDMA enhances hippocampal-dependent learning and memory under restrictive conditions, and modifies hippocampal spine density. Psychopharmacology, 231, 863-874. [CrossRef] [PubMed] [Google Scholar]
  • Abad, S., Camarasa, J., Pubill, D., Camins, A., Escubedo, E. (2016). Adaptive plasticity in the hippocampus of young mice intermittently exposed to MDMA could be the origin of memory deficits. Mol Neurobiol, 53, 7271-7283. [CrossRef] [PubMed] [Google Scholar]
  • Adori, C., Andó, R.D., Ferrington, L., Szekeres, M., Vas, S., Kelly, P.A.T., Hunyady, L., Bagdy, G. (2010). Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats: a potential link to the long-term recovery of serotonergic axons. Neurosci Lett, 478, 56-60. [CrossRef] [PubMed] [Google Scholar]
  • Angelucci, F., Ricci, V., Martinotti, G., Palladino, I., Spalletta, G., Caltagirone, C., Bria, P. (2010). Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise of drug-induced psychotic symptoms. Addict Biol, 15, 365-367. [CrossRef] [PubMed] [Google Scholar]
  • Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P., Kavalali, E.T., Monteggia, L.M. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 475, 91-95. [Google Scholar]
  • Baumeister, D., Barnes, G., Giaroli, G., Tracy, D. (2014). Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol, 4, 156-169. [CrossRef] [PubMed] [Google Scholar]
  • Becker, A., Grecksch, G., Schwegler, H., Roskoden, T. (2008). Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment. Med Chem Shariqah United Arab Emir, 4, 256-263. [Google Scholar]
  • Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J.A., Andrade, R. (2007). Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci USA, 104, 9870-9875. [CrossRef] [Google Scholar]
  • Benwell, M.E., Holtom, P.E., Moran, R.J., Balfour, D.J. (1996). Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br J Pharmacol, 117, 743-749. [CrossRef] [PubMed] [Google Scholar]
  • Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal, J.H. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47, 351-354. [Google Scholar]
  • Björkholm, C., Monteggia, L.M. (2016). BDNF − a key transducer of antidepressant effects. Neuropharmacology, 102, 72-79. [CrossRef] [PubMed] [Google Scholar]
  • Bogenschutz, M.P., Forcehimes, A.A., Pommy, J.A., Wilcox, C.E., Barbosa, P.C.R., Strassman, R.J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol, 29, 289-299. [CrossRef] [PubMed] [Google Scholar]
  • Caffino, L., Di Chio, M., Giannotti, G., Venniro, M., Mutti, A., Padovani, L., Cheung, D., Fumagalli, G.F., Yew, D.T., Fumagalli, F., Yew DT, Chiamulera C. (2016). The modulation of BDNF expression and signalling dissects the antidepressant from the reinforcing properties of ketamine: effects of single infusion vs. chronic self-administration in rats. Pharmacol Res, 104, 22-30. [CrossRef] [PubMed] [Google Scholar]
  • Carhart-Harris, R.L., Bolstridge, M., Day, C.M.J., Rucker, J., Watts, R., Erritzoe, D.E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard J.A., Forbes B., Feilding A., Taylor D., Curran H.V., Nutt D.J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235, 399-408. [CrossRef] [PubMed] [Google Scholar]
  • Castrén, E. (2014). Neurotrophins and psychiatric disorders. Handb Exp Pharmacol, 220, 461-479. [CrossRef] [PubMed] [Google Scholar]
  • Chaki, S. (2017). Beyond ketamine: new approaches to the development of safer antidepressants. Curr Neuropharmacol, 15, 963-976. [CrossRef] [PubMed] [Google Scholar]
  • Cui, W., Ning, Y., Hong, W., Wang, J., Liu, Z., Li, M.D. (2018). Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for ketamine’s antidepressant. Effect Mol Neurobiol, 56, 3484-3500. [CrossRef] [Google Scholar]
  • Dakwar, E., Levin, F., Foltin, R.W., Nunes, E.V., Hart, C.L. (2014). The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry, 76, 40-46. [CrossRef] [PubMed] [Google Scholar]
  • Dakwar, E., Hart, C.L., Levin, F.R., Nunes, E.V., Foltin, R.W. (2017). Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. Mol Psychiatry, 22, 76-81. [CrossRef] [PubMed] [Google Scholar]
  • Duman, R.S., Li, N. (2012). A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci, 367, 2475-2484. [CrossRef] [PubMed] [Google Scholar]
  • Duncan, W.C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B.A., Hejazi, N.S., Yuan, P., Brutsche, N., Manji, H.K., Tononi, G., Zarate C.A. (2013). Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol, 16, 301-311. [CrossRef] [PubMed] [Google Scholar]
  • Dunlap, L.E., Andrews, A.M., Olson, D.E. (2018). Dark classics in chemical neuroscience: 3,4-methylenedioxymethamphetamine. ACS Chem Neurosci, 9, 2408-2427. [PubMed] [Google Scholar]
  • Edut, S., Rubovitch, V., Rehavi, M., Schreiber, S., Pick, C.G. (2014). A study on the mechanism by which MDMA protects against dopaminergic dysfunction after minimal traumatic brain injury (mTBI) in mice. J Mol Neurosci, 54, 684-697. [CrossRef] [PubMed] [Google Scholar]
  • Feder, A., Parides, M.K., Murrough, J.W., Perez, A.M., Morgan, J.E., Saxena, S., Kirkwood, K., Aan Het Rot, M., Lapidus, K.A.B., Wan, L.-B., Iosifescu, D.V., Charney, D.S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry, 71, 681-688. [CrossRef] [PubMed] [Google Scholar]
  • Garcia, L.S.B., Comim, C.M., Valvassori, S.S., Réus, G.Z., Barbosa, L.M., Andreazza, A.C., Stertz, L., Fries, G.R., Gavioli, E.C., Kapczinski, F., Quevedo J. (2008). Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry, 32, 140-144. [CrossRef] [PubMed] [Google Scholar]
  • Garcia-Romeu, A., Griffiths, R.R., Johnson, M.W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev, 7, 157-164. [CrossRef] [PubMed] [Google Scholar]
  • Gewirtz, J.C., Chen, A.C., Terwilliger, R., Duman, R.C., Marek, G.J. (2002). Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav, 73, 317-326. [CrossRef] [PubMed] [Google Scholar]
  • Gibon, J., Barker, P.A. (2017). Neurotrophins and proneurotrophins: focus on synaptic activity and plasticity in the brain. Neuroscientist, 23, 587-604. [CrossRef] [PubMed] [Google Scholar]
  • Glick, S.D., Maisonneuve, I.M., Pearl, S.M. (1997). Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res, 749, 340-343. [CrossRef] [PubMed] [Google Scholar]
  • Grob, C.S., Danforth, A.L., Chopra, G.S., Hagerty, M., McKay, C.R., Halberstadt, A.L., Greer, G.R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry, 68, 71-78. [CrossRef] [PubMed] [Google Scholar]
  • Haile, C.N., Murrough, J.W., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Foulkes, A., Iqbal, S., Mahoney, J.J., De La Garza, R., Charney, D.S., Newton T.F., Mathew S.J. (2014). Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol, 17, 331-336. [CrossRef] [PubMed] [Google Scholar]
  • Hao, R., Qi, Y., Hou, D.-N., Ji, Y.-Y., Zheng, C.-Y., Li, C.-Y., Yung, W.-H., Lu, B., Huang, Y. (2017). BDNF val66met polymorphism impairs hippocampal long-term depression by down-regulation of 5-HT3 receptors. Front Cell Neurosci, 11, 306-327. [Google Scholar]
  • Hatami, H., Hossainpour-Faizi, M.A., Azarfarin, M., Azarfam, P. (2010). Chronic ecstasy use increases neurotrophin-4 gene expression and protein levels in the rat brain. Pharmacol Rep PR, 62, 998-1004. [CrossRef] [Google Scholar]
  • He, D.-Y., Ron, D. (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J, 20, 2420-2422. [CrossRef] [PubMed] [Google Scholar]
  • He, D.-Y., McGough, N.N.H., Ravindranathan, A., Jeanblanc, J., Logrip, M.L., Phamluong, K., Janak, P.H., Ron, D. (2005). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci, 25, 619-628. [CrossRef] [PubMed] [Google Scholar]
  • Hemmerle, A.M., Dickerson, J.W., Herring, N.R., Schaefer, T.L., Vorhees, C.V., Williams, M.T., Seroogy, K.B. (2012). (±)3,4-methylenedioxymethamphetamine (“ecstasy”) treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain. J Comp Neurol, 520, 2459-2474. [PubMed] [Google Scholar]
  • Jadhav, K.S., Boutrel, B. (2018). Prefrontal cortex development and emergence of self-regulatory competence: the two cardinal features of adolescence disrupted in context of alcohol abuse. Eur J Neurosci, doi: 10.1111/ejn.14316. [Epub ahead of print]. [Google Scholar]
  • Jha, S., Rajendran, R., Fernandes, K.A., Vaidya, V.A. (2008). 5-HT2A/2C receptor blockade regulates progenitor cell proliferation in the adult rat hippocampus. Neurosci Lett, 441, 210-214. [CrossRef] [PubMed] [Google Scholar]
  • Johnson, M.W., Garcia-Romeu, A., Cosimano, M.P., Griffiths, R.R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol, 28, 983-992. [CrossRef] [PubMed] [Google Scholar]
  • Kashyap, M.P., Roberts, C., Waseem, M., Tyagi, P. (2018). Drug targets in neurotrophin signaling in the central and peripheral nervous system. Mol Neurobiol, 55, 6939-6955. [CrossRef] [PubMed] [Google Scholar]
  • Ke, X., Ding, Y., Xu, K., He, H., Zhang, M., Wang, D., Deng, X., Zhang, X., Zhou, C., Liu, Y., Ning Y., Fan N. (2014). Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers. Drug Alcohol Depend, 142, 290-294. [CrossRef] [PubMed] [Google Scholar]
  • Klein, A.B., Santini, M.A., Aznar, S., Knudsen, G.M., Rios, M. (2010). Changes in 5-HT2A-mediated behavior and 5-HT2A- and 5-HT1A receptor binding and expression in conditional brain-derived neurotrophic factor knock-out mice. Neuroscience, 169, 1007-1016. [PubMed] [Google Scholar]
  • Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., Grinenko, A. (2002). Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat, 23, 273-283. [CrossRef] [PubMed] [Google Scholar]
  • Krupitsky, E.M., Burakov, A.M., Dunaevsky, I.V., Romanova, T.N., Slavina, T.Y., Grinenko, A.Y. (2007). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs, 39, 13-19. [CrossRef] [PubMed] [Google Scholar]
  • Krystal, J.H., Sanacora, G., Duman, R.S. (2013). Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry, 73, 1133-1141. [CrossRef] [PubMed] [Google Scholar]
  • Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F.J., Sanacora, G., Zarate C. Jr. (2012). Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry, 72, e27-e28. [CrossRef] [PubMed] [Google Scholar]
  • Lepack, A.E., Fuchikami, M., Dwyer, J.M., Banasr, M., Duman, R.S. (2014). BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol, 18(1), doi: 10.1093/ijnp/pyu033. [Google Scholar]
  • Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.-Y., Aghajanian, G., Duman, R.S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329, 959-964. [Google Scholar]
  • Lin, L.F., Doherty, D.H., Lile, J.D., Bektesh, S., Collins, F. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 260, 1130-1132. [Google Scholar]
  • Liu, R.-J., Lee, F.S., Li, X.-Y., Bambico, F., Duman, R.S., Aghajanian, G.K. (2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry, 71, 996-1005. [CrossRef] [PubMed] [Google Scholar]
  • Ly, C., Greb, A.C., Cameron, L.P., Wong, J.M., Barragan, E.V., Wilson, P.C., Burbach, K.F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M.R., Duim W.C., Dennis M.Y., McAllister A.K., Ori-McKenney K.M, Gray J.A, Olson D.E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Rep, 23, 3170-3182. [CrossRef] [PubMed] [Google Scholar]
  • Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H.K., Zarate, C.A. (2009). Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry, 70, 1662-1666. [CrossRef] [PubMed] [Google Scholar]
  • Marinova, Z., Walitza, S., Grünblatt, E. (2017). The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension. J Neural Transm, 124, 749-759. [CrossRef] [PubMed] [Google Scholar]
  • Martínez-Turrillas, R., Moyano, S., Del Río, J., Frechilla, D. (2006). Differential effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) on BDNF mRNA expression in rat frontal cortex and hippocampus. Neurosci Lett, 402, 126-130. [CrossRef] [PubMed] [Google Scholar]
  • Marton, S., González, B., Rodríguez-Bottero, S., Miquel, E., Martínez-Palma, L., Pazos, M., Prieto, J.P., Rodríguez, P., Sames, D., Seoane, G., Scorza C, Cassina P., Carrera I. (2019). Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Front Pharmacol, 10, 193. doi: 10.3389. [CrossRef] [PubMed] [Google Scholar]
  • Mithoefer, M.C., Wagner, M.T., Mithoefer, A.T., Jerome, L., Doblin, R. (2011). The safety and efficacy of {+/−}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol, 25, 439-452. [CrossRef] [PubMed] [Google Scholar]
  • Mithoefer, M.C., Wagner, M.T., Mithoefer, A.T., Jerome, L., Martin, S.F., Yazar-Klosinski, B., Michel, Y., Brewerton, T.D., Doblin, R. (2013). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol, 27, 28-39. [CrossRef] [PubMed] [Google Scholar]
  • Mouri, A., Noda, Y., Niwa, M., Matsumoto, Y., Mamiya, T., Nitta, A., Yamada, K., Furukawa, S., Iwamura, T., Nabeshima, T. (2017). The involvement of brain-derived neurotrophic factor in 3,4-methylenedioxymethamphetamine-induced place preference and behavioral sensitization. Behav Brain Res, 329, 157-165. [CrossRef] [PubMed] [Google Scholar]
  • Murrough, J.W., Perez, A.M., Pillemer, S., Stern, J., Parides, M.K., aan het Rot, M., Collins, K.A., Mathew, S.J., Charney, D.S., Iosifescu, D.V. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry, 74, 250-256. [CrossRef] [PubMed] [Google Scholar]
  • Nau, F., Miller, J., Saravia, J., Ahlert, T., Yu, B., Happel, K.I., Cormier, S.A., Nichols, C.D. (2015). Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model. Am J Physiol Lung Cell Mol Physiol, 308, L191-L198. [CrossRef] [PubMed] [Google Scholar]
  • Nichols, D.E. (2016). Psychedelics. Pharmacol Rev, 68, 264-355. [CrossRef] [PubMed] [Google Scholar]
  • Park, H., Poo, M. (2013). Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci, 14, 7-23. [CrossRef] [PubMed] [Google Scholar]
  • Rantamäki, T. (2019). TrkB neurotrophin receptor at the core of antidepressant effects, but how? Cell Tissue Res, doi: 10.1007/s00441-018-02985-6. [Epub ahead of print]. [Google Scholar]
  • Rasmussen, K.G., Lineberry, T.W., Galardy, C.W., Kung, S., Lapid, M.I., Palmer, B.A., Ritter, M.J., Schak, K.M., Sola, C.L., Hanson, A.J., Frye M.A. (2013). Serial infusions of low-dose ketamine for major depression. J Psychopharmacol, 27, 444-450. [CrossRef] [PubMed] [Google Scholar]
  • Ricci, V., Martinotti, G., Gelfo, F., Tonioni, F., Caltagirone, C., Bria, P., Angelucci, F. (2011). Chronic ketamine use increases serum levels of brain-derived neurotrophic factor. Psychopharmacology (Berl.), 215, 143-148. [Google Scholar]
  • Robertson, O.D., Coronado, N.G., Sethi, R., Berk, M., Dodd, S. (2019). Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Interv Psychiatry, doi: 10.1111/eip.12775. [Epub ahead of print]. [Google Scholar]
  • Rybakowski, J.K., Permoda-Osip, A., Skibinska, M., Adamski, R., Bartkowska-Sniatkowska, A. (2013). Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol, 28, 87-90. [CrossRef] [PubMed] [Google Scholar]
  • Sanacora, G., Frye, M.A., McDonald, W., Mathew, S.J., Turner, M.S., Schatzberg, A.F., Summergrad, P., Nemeroff, C.B., American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74, 399-405. [CrossRef] [PubMed] [Google Scholar]
  • Singh, J.B., Fedgchin, M., Daly, E.J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J.W., Sanacora, G., Shelton, R.C., Kurian B., Winokur A., Fava M., Manji H., Drevets WC., Van Nueten L. (2016). A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry, 173, 816-826. [CrossRef] [PubMed] [Google Scholar]
  • Skaper, S.D. (2018). Neurotrophic factors: an overview. Methods Mol Biol, 1727, 1-17. [CrossRef] [PubMed] [Google Scholar]
  • Soleimani Asl, S., Hesam Shariati, M.B., Medizadeh, M., Ahmadpanah, M., Sohrabi, M. (2017). The effect of 3,4-methylenedioxymethamphetamine on expression of neurotrophic factors in hippocampus of male rats. Med J Islam Repub Iran, 31, 60-71. [Google Scholar]
  • Strasburger, S.E., Bhimani, P.M., Kaabe, J.H., Krysiak, J.T., Nanchanatt, D.L., Nguyen, T.N., Pough, K.A., Prince, T.A., Ramsey, N.S., Savsani, K.H., Scandlen L., Cavaretta M.J., Raffa R.B. (2017). What is the mechanism of ketamine’s rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. J Clin Pharm Ther, 42, 147-154. [CrossRef] [PubMed] [Google Scholar]
  • Vaidya, V.A., Marek, G.J., Aghajanian, G.K., Duman, R.S. (1997). 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci, 17, 2785-2795. [CrossRef] [PubMed] [Google Scholar]
  • Vargas-Perez, H., Grieder, T.E., Ting-A-Kee, R., Maal-Bared, G., Chwalek, M., van der Kooy, D. (2017). A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents. Eur J Neurosci, 45, 1410-1417. [CrossRef] [PubMed] [Google Scholar]
  • Wilkinson, S.T., Ballard, E.D., Bloch, M.H., Mathew, S.J., Murrough, J.W., Feder, A., Sos, P., Wang, G., Zarate, C.A., Sanacora, G. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry, 175, 150-158. [CrossRef] [PubMed] [Google Scholar]
  • Young, M.B., Norrholm, S.D., Khoury, L.M., Jovanovic, T., Rauch, S.A.M., Reiff, C.M., Dunlop, B.W., Rothbaum, B.O., Howell, L.L. (2017). Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology (Berl.), 234, 2883-2895. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.